NDATOPICALDRESSING
Approved
Nov 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SILDAFLO (silver sulfadiazine) by Inpharmus is clinical pharmacology silver sulfadiazine has broad antimicrobial activity. First approved in 1989.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SILDAFLO is a topical silver sulfadiazine 1% cream dressing with broad-spectrum bactericidal activity against gram-negative and gram-positive bacteria as well as yeast. It works by acting on the bacterial cell wall to inhibit pathogens resistant to other antimicrobial agents. The product is indicated for burn wound care and other topical antimicrobial applications.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating limited team expansion and focus on managed decline strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below. Sufficient data have been obtained to demonstrate that silver…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SILDAFLO at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.